Although about 20% of patients with advanced NSCLC can benefit from immune checkpoint inhibitors (ICIs),9 patients with EGFR‐TKI resistance do not benefit from ICI monotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.